Screw it, double down man.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Something seems amiss I will say.
Maybe fraud is too much, but there are things that do not sit well with me
He doesn’t, no one knows the drip out numbers yet
Geert rushed a Pr that spooked the market and now everyone panic sold and/or is waiting for Talor to explain the results tomorrow at 10am.
Shorts took advantage
Trading right at the resistance.
A close over $2.60 is very bullish
BTIG initiated shares as a buy with a price target of $14.
B. Riley said the results beat expectations, especially with regards to suicidality, leading to a buy reiteration and $15 price target.
Trades at $2.64.
Bounced off the bottom of $2.60.
Ketamine PH3 about to start
I got stopped out.
Took the bulk of my cash to SEEL.
Seel Added to the Russell 2000,Russell 3000, and Russell Microcap.
-Seel Announces its Inclusion in the First U.S. Listed (ETF) Focused on Psychedelics
-Seel Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS)
I believe the decision on treatment protocols is made well before the cut into you.
SEEL - some pretty decent market buys. They gotta be starting their SLS-002 Ketamine PH3 soon yeah? @seelostx
Priority drug voucher for SLS-005?
$56M cash?!
Massive pipeline…..
You are a peddler of half truths.
Speculation and lies.
Correct.
This guy gets it https://twitter.com/nucleotidesoup/status/1409636992573349889?s=21
Adam F aka Sushi…. Posting about sushi
I don't like to call out "civilians" ie retail investors, but I will make an exception for the "Kill $CVM shorts" guy aka "Sushifishman" among many other aliases he uses on social media and across the Internet.
— Adam Feuerstein ✡️ (@adamfeuerstein) June 29, 2021
No. I assume dropouts were not that bad and the non chemo group is larger than most believe.
1. The SOC beat wasn’t a subset, it was a full arm of the study.
2. I’m sure there is a ton of data to go through still.
3. What if after ALL the data is realized the P value improves even more that the already great result?
4. They have $47M in cash.
5. They FDA would be crazy to not approve this.
Excited for the SHM
People seem to forget that Keytruda’s first approval was for a subgroup of about 100 patients. It is now set to become the highest revenue generating drug in the world.
It showed less of an improvement over SOC the Multikine.
Insiders added yesterday.
Massive overreaction
Keytruda’s first approval was for a subgroup of about 100 patients. It is now set to become the highest revenue generating drug in the world.
I would like to see the math problem for OS question answered.
Group size, tumor reduction…
And I would like to see Geert but more shares.
“Submission policies
When you submit a manuscript to Scientific Reports, we will take it to imply that the manuscript has not already been published or submitted elsewhere….You may not submit your manuscript elsewhere while it is under consideration”
https://www.nature.com/srep/journal-policies/editorial-policies
Here is your answer : Geert tweet , “The details of the $CVM study will end up being published in one or more peer reviewed scientific publications. We cannot announce the details because that would preclude publication in the top journals. This is how data is typically disseminated.”
Did you submit the question?
I am also very curious why the OS was not listed as 29%……!? Why use different math. Both are good but 29% is great.
Two new positions for hire added today on CVM website…..
$CVM I tip my hat in respect of the short sellers ability to make the great survival benefit with no safety issues look bad. Unreal. This reminds me of when we won the arbitration against Inventiv, a huge win, and the stock declined. I bought over 300,000 shares at $0.84. pic.twitter.com/wc1sj18ECP
— Geert Kersten (@GeertKersten1) June 29, 2021
I would really like to see the full data.
Tumor reduction?
Quality of life?
How large was the non chemo group?
It held above a $500M mc which is impressive with the shorting today.
15M volume between $13-$14.50.
Lots of unanswered questions.
But it’s clear multikine is better than chemo.
What are your questions for the SHM?
Good question.
210,000*
News : Kingswood bought the over allotment of 220,000 shares. https://newsfilter.io/a/02200e40687555e3005c3f068aff1218
I thought there would be more volume… lots of longs holding, not a lot of covering by shorts
Would love to see Geert buy a chunk today.
There are no shares available to short per fintel… $14 seems to be the bottom for now.
Nontoxic cancer treatment!
Haven’t sold a share
Still a great BO candidate and likely approval With orphan drug status.
$CVM Ph3 study shows great overall survival benefit (ITT) of 14.1% (62.7% vs 48.6%) at 5 yrs. No safety issues. Outstanding p=0.0236, Hazard ratio=0.68. Survival increases over time. We plan to seek FDA approval for this unmet need
Yup, and not even enough volume for them to cover…..
Still a great BO candidate
7M traded. Shorts gotta cover 10M
A lot are still holding
No, no it wasnt
Rebounding.
This was a coordinated short attack
Haven’t sold. Looking to add.
$CVM Such amount of misinformation. Great data and we believe very approvable. The analysis we did was included in the protocol and the Statistical Analysis Plan and is therefore acceptable to FDA. The group is 1 of 2 and represents over 150,000 patients.
— Geert Kersten (@GeertKersten1) June 28, 2021